AZENTA INC(NASDAQ:AZTA) stock Fundamental Analysis

Fundamental Rating

Taking everything into account, AZTA scores 5 out of 10 in our fundamental rating. AZTA was compared to 57 industry peers in the Life Sciences Tools & Services industry. While AZTA has a great health rating, there are worries on its profitability. AZTA is valied quite expensively at the moment, while it does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year AZTA was profitable.

AZTA had a positive operating cash flow in the past year.

The reported net income has been mixed in the past 5 years: AZTA reported negative net income in multiple years.

Of the past 5 years AZTA 4 years had a positive operating cash flow.

1.2 Ratios

AZTA has a Return On Assets of -7.93%. This is in the better half of the industry: AZTA outperforms 61.40% of its industry peers.

AZTA has a better Return On Equity (-9.41%) than 66.67% of its industry peers.

		Industry Rank	Sector Rank
ROA	-7.93%
ROE	-9.41%
ROIC	N/A

ROA(3y)16.36%

ROA(5y)11.87%

ROE(3y)17.86%

ROE(5y)13.45%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

AZTA has a Gross Margin (41.65%) which is in line with its industry peers.

AZTA's Gross Margin has been stable in the last couple of years.

AZTA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	41.65%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-5.44%

GM growth 5Y-0.19%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

AZTA does not have a ROIC to compare to the WACC, probably because it is not profitable.

AZTA has less shares outstanding than it did 1 year ago.

Compared to 5 years ago, AZTA has less shares outstanding

Compared to 1 year ago, AZTA has a worse debt to assets ratio.

2.2 Solvency

An Altman-Z score of 5.42 indicates that AZTA is not in any danger for bankruptcy at the moment.

With an excellent Altman-Z score value of 5.42, AZTA belongs to the best of the industry, outperforming 80.70% of the companies in the same industry.

There is no outstanding debt for AZTA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	0
Altman-Z	5.42

ROIC/WACCN/A

WACC11.32%

2.3 Liquidity

AZTA has a Current Ratio of 4.18. This indicates that AZTA is financially healthy and has no problem in meeting its short term obligations.

Looking at the Current ratio, with a value of 4.18, AZTA is in the better half of the industry, outperforming 64.91% of the companies in the same industry.

A Quick Ratio of 3.78 indicates that AZTA has no problem at all paying its short term obligations.

The Quick ratio of AZTA (3.78) is better than 64.91% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	4.18
Quick Ratio	3.78

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

AZTA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 113.64%, which is quite impressive.

Measured over the past years, AZTA shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -12.07% on average per year.

The Revenue has been growing slightly by 1.33% in the past year.

AZTA shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -3.41% yearly.

EPS 1Y (TTM)113.64%

EPS 3Y-45.83%

EPS 5Y-12.07%

EPS Q2Q%300%

Revenue 1Y (TTM)1.33%

Revenue growth 3Y8.51%

Revenue growth 5Y-3.41%

Sales Q2Q%-4.41%

3.2 Future

Based on estimates for the next years, AZTA will show a very strong growth in Earnings Per Share. The EPS will grow by 37.37% on average per year.

AZTA is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 0.32% yearly.

EPS Next Y24.39%

EPS Next 2Y41.7%

EPS Next 3Y37.37%

EPS Next 5YN/A

Revenue Next Year-9.1%

Revenue Next 2Y-1.7%

Revenue Next 3Y0.32%

Revenue Next 5YN/A

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 95.21, the valuation of AZTA can be described as expensive.

AZTA's Price/Earnings ratio is in line with the industry average.

When comparing the Price/Earnings ratio of AZTA to the average of the S&P500 Index (29.63), we can say AZTA is valued expensively.

A Price/Forward Earnings ratio of 54.36 indicates a quite expensive valuation of AZTA.

AZTA's Price/Forward Earnings ratio is in line with the industry average.

When comparing the Price/Forward Earnings ratio of AZTA to the average of the S&P500 Index (22.68), we can say AZTA is valued expensively.

		Industry Rank	Sector Rank
PE	95.21
Fwd PE	54.36

4.2 Price Multiples

AZTA's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. AZTA is cheaper than 64.91% of the companies in the same industry.

The rest of the industry has a similar Price/Free Cash Flow ratio as AZTA.

		Industry Rank	Sector Rank
P/FCF	100.09
EV/EBITDA	52.13

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.

AZTA's earnings are expected to grow with 37.37% in the coming years. This may justify a more expensive valuation.

PEG (NY)3.9

PEG (5Y)N/A

EPS Next 2Y41.7%

EPS Next 3Y37.37%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for AZTA!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

AZENTA INC

NASDAQ:AZTA (2/21/2025, 8:02:34 PM)

After market: 44.79 +0.04 (+0.09%)

44.75

-0.03 (-0.07%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryLife Sciences Tools & Services

Earnings (Last)02-05 2025-02-05/bmo

Earnings (Next)05-06 2025-05-06/amc

Inst Owners115.49%

Inst Owner ChangeN/A

Ins Owners0.69%

Ins Owner Change13.59%

Market Cap2.05B

Analysts74.29

Price Target57.8 (29.16%)

Short Float %9.16%

Short Ratio7.36

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly Dividend0

Dividend Growth(5Y)N/A

DP0%

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)54.54%

Min EPS beat(2)37.26%

Max EPS beat(2)71.81%

EPS beat(4)4

Avg EPS beat(4)98.59%

Min EPS beat(4)37.26%

Max EPS beat(4)162.56%

EPS beat(8)7

Avg EPS beat(8)212.82%

EPS beat(12)11

Avg EPS beat(12)159.27%

EPS beat(16)14

Avg EPS beat(16)124.06%

Revenue beat(2)0

Avg Revenue beat(2)-1.39%

Min Revenue beat(2)-1.7%

Max Revenue beat(2)-1.07%

Revenue beat(4)1

Avg Revenue beat(4)-0.82%

Min Revenue beat(4)-2.43%

Max Revenue beat(4)1.9%

Revenue beat(8)4

Avg Revenue beat(8)-0.51%

Revenue beat(12)6

Avg Revenue beat(12)-0.88%

Revenue beat(16)7

Avg Revenue beat(16)-11.36%

PT rev (1m)0.6%

PT rev (3m)-4.31%

EPS NQ rev (1m)26.3%

EPS NQ rev (3m)-10.66%

EPS NY rev (1m)21.53%

EPS NY rev (3m)19.74%

Revenue NQ rev (1m)-3.35%

Revenue NQ rev (3m)-16.99%

Revenue NY rev (1m)-0.08%

Revenue NY rev (3m)-14.64%

Valuation

		Industry Rank	Sector Rank
PE	95.21
Fwd PE	54.36
P/S	3.15
P/FCF	100.09
P/OCF	37.53
P/B	1.19
P/tB	2.2
EV/EBITDA	52.13

EPS(TTM)0.47

EY1.05%

EPS(NY)0.82

Fwd EY1.84%

FCF(TTM)0.45

FCFY1%

OCF(TTM)1.19

OCFY2.66%

SpS14.21

BVpS37.61

TBVpS20.36

PEG (NY)3.9

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-7.93%
ROE	-9.41%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	41.65%
FCFM	3.15%

ROA(3y)16.36%

ROA(5y)11.87%

ROE(3y)17.86%

ROE(5y)13.45%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-5.44%

GM growth 5Y-0.19%

F-Score6

Asset Turnover0.32

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	0
Debt/EBITDA	0
Cap/Depr	39.15%
Cap/Sales	5.24%
Interest Coverage	N/A
Cash Conversion	189.73%
Profit Quality	N/A
Current Ratio	4.18
Quick Ratio	3.78
Altman-Z	5.42

F-Score6

WACC11.32%

ROIC/WACCN/A

Cap/Depr(3y)77.14%

Cap/Depr(5y)74.64%

Cap/Sales(3y)8.52%

Cap/Sales(5y)9.22%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)113.64%

EPS 3Y-45.83%

EPS 5Y-12.07%

EPS Q2Q%300%

EPS Next Y24.39%

EPS Next 2Y41.7%

EPS Next 3Y37.37%

EPS Next 5YN/A

Revenue 1Y (TTM)1.33%

Revenue growth 3Y8.51%

Revenue growth 5Y-3.41%

Sales Q2Q%-4.41%

Revenue Next Year-9.1%

Revenue Next 2Y-1.7%

Revenue Next 3Y0.32%

Revenue Next 5YN/A

EBIT growth 1Y14.17%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year1022.7%

EBIT Next 3Y157.38%

EBIT Next 5YN/A

FCF growth 1Y103.52%

FCF growth 3Y-48.98%

FCF growth 5Y-28.07%

OCF growth 1Y110.71%

OCF growth 3Y-30.52%

OCF growth 5Y-11.17%

AZENTA INC (AZTA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens